Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Non-Current Liabilities: 2016-2025

Historic Total Non-Current Liabilities for Anaptysbio (ANAB) over the last 6 years, with Sep 2025 value amounting to $50.7 million.

  • Anaptysbio's Total Non-Current Liabilities fell 13.37% to $50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year decrease of 13.37%. This contributed to the annual value of $59.5 million for FY2024, which is 11.33% up from last year.
  • Anaptysbio's Total Non-Current Liabilities amounted to $50.7 million in Q3 2025, which was up 4.21% from $48.6 million recorded in Q2 2025.
  • Anaptysbio's Total Non-Current Liabilities' 5-year high stood at $59.5 million during Q4 2024, with a 5-year trough of $35.5 million in Q4 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $55.5 million (2024), whereas its average is $54.5 million.
  • As far as peak fluctuations go, Anaptysbio's Total Non-Current Liabilities surged by 52.06% in 2023, and later dropped by 13.37% in 2025.
  • Quarterly analysis of 5 years shows Anaptysbio's Total Non-Current Liabilities stood at $35.5 million in 2021, then increased by 23.40% to $43.9 million in 2022, then rose by 21.91% to $53.5 million in 2023, then climbed by 11.33% to $59.5 million in 2024, then dropped by 13.37% to $50.7 million in 2025.
  • Its Total Non-Current Liabilities stands at $50.7 million for Q3 2025, versus $48.6 million for Q2 2025 and $57.6 million for Q1 2025.